New herbal composition (OA-F2) protects cartilage degeneration in a rat model of collagenase induced osteoarthritis.
新規ハーブ組成物(OA-F2)はコラゲナーゼ誘発変形性関節症ラットモデルにおける軟骨変性を保護する (機械翻訳の邦題)
記録の確認項目
- 研究デザイン
- その他の原著論文
- 対象
- ヒト・動物 併記
- 出版年
- 2017
- 出典
- doi.org
- 抄録の表示
- 表示あり
- 出版状態
- 有効な記録
- 状態確認日
- 2026/08/17
- 収集日
- 2026/08/04
- 鮮度
- 確認期限内
- 確認段階
- 自動処理
- 記録状態
- 公開
日本語要約(機械生成)
変形性関節症(OA)の治療薬開発を目的に、Sida cordifoliaとZingiber officinaleを含むハーブ製剤OA-F2の効果を、コラゲナーゼ誘発OAラットモデルで検討した。OA-F2を3用量(135、270、540 mg/kg)で20日間経口投与し、ジクロフェナクを対照とした。その結果、OA-F2は膝腫脹と足容積を有意に抑制し、疼痛関連行動を改善した。血清CRP、ALP、GAGレベルを有意に低下させ、X線および組織学的に軟骨保護を示した。また、滑膜組織において抗酸化酵素(SOD、GPx、CAT)の発現を上昇させ、MMP-3およびMMP-9の発現を低下させ、TIMP-1の発現を上昇させた。これらの結果から、OA-F2はMMP制御と抗酸化能向上を介して軟骨保護効果を示し、OA治療薬として有望である。
この要約は公開抄録のみを根拠にAIが機械的に生成したものです。正確な内容は原文を確認してください。
抄録
Background: Prevalence of osteoarthritis (OA) is on rise on the global scale. At present there are no satisfactory pharmacological agents for treating OA. Our previous study showed that Sida cordifolia L. and Zingiber officinale Rosc. had protective effect on cartilage. Here, we describe the effect of OA-F2, a herbal formulation prepared using combination of these two plants in alleviating OA associated symptoms in a rat model of collagenase-induced OA.Methods: OA was induced by intra-articular injection of collagenase type II in wistar rats. Diclofenac (10 mg/kg) was used as a reference control. Rats (n = 6) were divided into 6 groups: Healthy control (HC), osteoarthritic control (OAC), diclofenac (DICLO), OA-F2L (135 mg/kg), OA-F2M (270 mg/kg) and OA-F2H (540 mg/kg). The effects of the 20 days treatment were monitored by parameters like knee diameter, paw volume, paw retraction; serum C-reactive protein (CRP), alkaline phosphatase (ALP) and glycosaminoglycan (GAG). Radiography and histopathology of knee joint were also studied. Additionally, gene expression was studied from isolated synovium tissue proving anti-osteoarthritic potential of OA-F2.Results: Oral administration of OA-F2 has significantly prevented knee swelling compared to OAC; OA-F2 and DICLO, significantly reduced paw volume compared to OAC. Paw latency was remarkably increased by OA-F2 compared to OAC. OA-F2L (-0.670, p < 0.001), M (-0.110, p < 0.05) and H (0.073) has markedly reduced levels of CRP compared to DICLO. OA-F2L (p < 0.05), M (p < 0.001) and H (p < 0.05) significantly reduced ALP levels, compared to DICLO. GAG release in the serum was also significantly lowered in OA-F2 treated group compared to DICLO. Radiological and histopathological observations showed cartilage protection by OA-F2. OA-F2 has upregulated SOD and GPx. Upregulated CAT expression was observed in OA-F2M and H. Considerable down-regulation of expression of MMP-3 and MMP-9 was observed in all the groups. Up-regulation of TIMP-1 was observed in rats treated with OA-F2L, H and DICLO.Conclusion: OA-F2 has shown therapeutic effects in rat model of collagenase induced OA by demonstrating cartilage protection through controlling MMPs and improving anti-oxidant levels in arthritic synovium and is a potent candidate for further drug development and treatment for OA.
MeSH
DOI 10.1186/s12906-016-1535-9
PMID 28049462
原文・出典を見る →